THUNDER BAY, Ontario--(BUSINESS WIRE)--Mitomics, world leader in the research and development of mitochondrial genome-based products, today announced it has entered into a non-exclusive agreement with Bostwick Laboratories, a leading full-service medical laboratory at the forefront of urologic pathology, to expand the sales and marketing of Mitomics’ flagship product, the Prostate Core Mitomic Test™ (PCMT), across the United States. Bostwick Laboratories will market the Mitomic Technology™ under the name ProstaClear™ Mitomic Test (PCMT).
